Historical Valuation
Ligand Pharmaceuticals Inc (LGND) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.95 is considered Undervalued compared with the five-year average of -9.93. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 816.57 to 859.81 according to relative valuation methord. Compared to the current price of 200.06 USD , Ligand Pharmaceuticals Inc is Undervalued By 75.5%.
Relative Value
Fair Zone
816.57-859.81
Current Price：200.06
75.5%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Ligand Pharmaceuticals Inc (LGND) has a current Price-to-Book (P/B) ratio of 3.93. Compared to its 3-year average P/B ratio of 2.37 , the current P/B ratio is approximately 65.88% higher. Relative to its 5-year average P/B ratio of 2.42, the current P/B ratio is about 62.60% higher. Ligand Pharmaceuticals Inc (LGND) has a Forward Free Cash Flow (FCF) yield of approximately 0.82%. Compared to its 3-year average FCF yield of 4.67%, the current FCF yield is approximately -82.39% lower. Relative to its 5-year average FCF yield of 4.42% , the current FCF yield is about -81.40% lower.
P/B
Median3y
2.37
Median5y
2.42
FCF Yield
Median3y
4.67
Median5y
4.42
Competitors Valuation Multiple
AI Analysis for LGND
The average P/S ratio for LGND competitors is 234.48, providing a benchmark for relative valuation. Ligand Pharmaceuticals Inc Corp (LGND.O) exhibits a P/S ratio of 14.95, which is -93.63% above the industry average. Given its robust revenue growth of 122.85%, this premium appears sustainable.
Performance Decomposition
AI Analysis for LGND
1Y
3Y
5Y
Market capitalization of LGND increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LGND in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LGND currently overvalued or undervalued?
Ligand Pharmaceuticals Inc (LGND) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.95 is considered Undervalued compared with the five-year average of -9.93. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 816.57 to 859.81 according to relative valuation methord. Compared to the current price of 200.06 USD , Ligand Pharmaceuticals Inc is Undervalued By 75.50% .
What is Ligand Pharmaceuticals Inc (LGND) fair value?
LGND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 816.57 to 859.81 according to relative valuation methord.
How does LGND's valuation metrics compare to the industry average?
The average P/S ratio for LGND's competitors is 234.48, providing a benchmark for relative valuation. Ligand Pharmaceuticals Inc Corp (LGND) exhibits a P/S ratio of 14.95, which is -93.63% above the industry average. Given its robust revenue growth of 122.85%, this premium appears sustainable.
What is the current P/B ratio for Ligand Pharmaceuticals Inc (LGND) as of Jan 09 2026?
As of Jan 09 2026, Ligand Pharmaceuticals Inc (LGND) has a P/B ratio of 3.93. This indicates that the market values LGND at 3.93 times its book value.
What is the current FCF Yield for Ligand Pharmaceuticals Inc (LGND) as of Jan 09 2026?
As of Jan 09 2026, Ligand Pharmaceuticals Inc (LGND) has a FCF Yield of 0.82%. This means that for every dollar of Ligand Pharmaceuticals Inc’s market capitalization, the company generates 0.82 cents in free cash flow.
What is the current Forward P/E ratio for Ligand Pharmaceuticals Inc (LGND) as of Jan 09 2026?
As of Jan 09 2026, Ligand Pharmaceuticals Inc (LGND) has a Forward P/E ratio of 35.39. This means the market is willing to pay $35.39 for every dollar of Ligand Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Ligand Pharmaceuticals Inc (LGND) as of Jan 09 2026?
As of Jan 09 2026, Ligand Pharmaceuticals Inc (LGND) has a Forward P/S ratio of 14.95. This means the market is valuing LGND at $14.95 for every dollar of expected revenue over the next 12 months.